Mitchell Shiffman REFERENCE: N Engl J Med 2007;357:124-34 MITCHELL SHIFFMAN, Virginia Commonwealth University, Richmond Standard anti-viral therapy for Hepatitis C needs to be used to the full duratio
Mitchell Shiffman
REFERENCE: N Engl J Med 2007;357:124-34MITCHELL SHIFFMAN, Virginia Commonwealth University, RichmondStandard anti-viral therapy for Hepatitis C needs to be used to the full duration according to a publication in the New England Journal of Medicine. Following provocative evidence from previous smaller studies, suggesting that anti viral therapy can be shortened, the ACCELERATE trial (the largest international study with genotypes 2 and 3) was set up to resolve whether shortening the duration of therapy for patients would give the same virologic response rates as with the standard regimen. It found that full-dose, full-duration therapy with interferon and ribavirin needs to be adhered to. Nicola Solomon interviewedMitchell Shiffmanto find out more.
Related Episodes
Obesity, Car Travel, Climate Change: Linked?
Phil Edwards Phil Edwards, London School of Hyugiene and Tropical Medicine LSHTM Audio News Obesity Linked to Motor Transport And Climate Change Peter Goodwin questions Phil Edwards of the London Scho
Blind For Blindness: Preventing Childhood Blindness
Hessom Razavi, Puneet Sayal, Claire Gilbert Hessom Razavi, Puneet Sayal, Claire Gilbert, London School of Hygiene and Tropical Medicine Eye doctor Hessom Razavi volunteered to go about his usual studi
Audio Journal of Medicine
In this edition: 1. Training In Depression And Suicide: Need For Change? Stan Kutcher, Dalhousie University, Nova Scotia 2. Suicide Paradox Explained: Australian National Strategy Barry Nurcombe, Prin